Loading...
•
Mar 31, 2021
Puma Biotechnology Q1 2021 Earnings Report
Puma Biotechnology's financial performance improved in Q1 2021, with a significant increase in total revenue and a shift to net income, driven by license revenue and Nerlynx sales.
Key Takeaways
Puma Biotechnology reported a net income of $16.5 million, or $0.40 per diluted share, for the first quarter of 2021, compared to a net loss of $16.9 million, or $0.43 per share, for the first quarter of 2020. Total revenue increased to $98.2 million, driven by $50.0 million in license revenue and $45.8 million in net product revenue. The company had cash, cash equivalents and marketable securities of $109.1 million at the end of the quarter.
Puma Biotechnology reported a net income of $16.5 million, a significant turnaround from the net loss of $16.9 million in the same quarter last year.
Total revenue surged to $98.2 million, primarily due to a substantial increase in license revenue to $50.0 million.
Net product revenue from NERLYNX was $45.8 million, slightly lower than the $48.6 million in the first quarter of 2020.
The company's cash, cash equivalents, and marketable securities stood at $109.1 million as of March 31, 2021.
Revenue by Segment
Forward Guidance
Puma Biotechnology anticipates several key milestones over the next 12 months, including reporting top line data from the Phase II SUMMIT trial, conducting a pre-NDA meeting with the FDA, and receiving regulatory decisions for the extended adjuvant HER2-positive early stage breast cancer indication in additional countries.
Positive Outlook
- Reporting top line data from the randomized cohort of the Phase II SUMMIT trial of neratinib in hormone receptor positive breast cancer that has a HER2 mutation (2021).
- Reporting Phase II data from the SUMMIT trial of neratinib in non-small cell lung cancer patients with EGFR exon 18 mutations (H2-2021).
- Conducting a pre-NDA meeting with the FDA to discuss accelerated approval of neratinib in HER2-mutated hormone receptor positive breast cancer and HER2-mutated cervical cancer (2021).
- Reporting data from the Phase II TBCRC-022 trial of the combination of Kadcyla plus neratinib in patients with HER2-positive breast cancer with brain metastases who have previously been treated with Kadcyla (H2-2021).
- Conducting a meeting with the FDA to discuss the potential for an accelerated approval pathway for neratinib in non-small cell lung cancer patients with EGFR exon 18 mutations who have previously been treated with an EGFR tyrosine kinase inhibitor (2021).
Challenges Ahead
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...